Cobimetinib (GDC-0973, XL-518) is a MEK inhibitor being developed by Exelixis and Roche. It is being studied in combination with Vemurafenib to treat several cancers, including Melanoma.

Dysregulated MAPK signaling is implicated in a wide range of cancers and occurs via multiple mechanisms. Abnormal expression or activating mutations in receptors, such as EGFR, may lead to overactive MAPK signaling. Additionally, activating KRAS and BRAF mutations that are exhibited in a large number of solid tumors lead to overactive MAPK signaling and may confer resistance to chemotherapeutic and targeted agents.

The inhibition of MAPK signaling with agents targeted toward critical proteins in the pathway, such as MEK, has the potential to inhibit growth in a variety of tumor types. Cobimetinib (GDC-0973) is an orally bioavailable inhibitor designed to selectively target MEK without perturbing its ATP site.

Suggested Pages #

• 0.025 Oncogene
• 0.025 Gefitinib
• 0.025 Ras GTPase
• 0.025 October 31
• 0.025 FOSL1
• 0.025 RAS
• 0.025 2017
• 0.025 2016
• 0.025 December 21
• 0.025 Nature Communications
• More suggestions...